Mirum Pharmaceuticals Inc...
(MIRM)
undefined
undefined%
At close: undefined
42.80
0.09%
After-hours Jan 03, 2025, 04:00 PM EST
Company Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis.
Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 311 |
| CEO | Christopher Peetz |
Contact Details
Address: 950 Tower Lane Foster City, California United States | |
| Website | https://www.mirumpharma.com |
Stock Details
| Ticker Symbol | MIRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001759425 |
| CUSIP Number | 604749101 |
| ISIN Number | US6047491013 |
| Employer ID | 83-1281555 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Peetz | Chief Executive Officer & Director |
| Eric H. Bjerkholt M.B.A. | Chief Financial Officer |
| Peter Radovich M.B.A., Ph.D. | Chief Operating Officer & President |
| Andrew McKibben | Vice President of Investor Relations and Finance |
| Dr. Jean-Luc Girardet Ph.D. | Senior Vice President of Technical Operations |
| Dr. Pamela Vig Ph.D. | Chief Scientific Officer |
| Erin Campany | Senior Vice President of Human Resources |
| Lara Longpre MBA, MSC | Chief Development Officer |
| Paul K. Ross | Chief Compliance Officer |
| Vinita P. Kumar | Senior vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 4 | Filing |
| Nov 14, 2024 | 4 | Filing |
| Nov 14, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |